JP2017511379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511379A5 JP2017511379A5 JP2017501529A JP2017501529A JP2017511379A5 JP 2017511379 A5 JP2017511379 A5 JP 2017511379A5 JP 2017501529 A JP2017501529 A JP 2017501529A JP 2017501529 A JP2017501529 A JP 2017501529A JP 2017511379 A5 JP2017511379 A5 JP 2017511379A5
- Authority
- JP
- Japan
- Prior art keywords
- modified antibody
- antibody
- modified
- cysteine
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1405264.1 | 2014-03-24 | ||
| GB201405264A GB201405264D0 (en) | 2014-03-24 | 2014-03-24 | Modified antibodies containing lgG2 Domains which possess agonist or antagonistic properties and therapeutic use thereof |
| GB1405275.7 | 2014-03-25 | ||
| GB201405275A GB201405275D0 (en) | 2014-03-25 | 2014-03-25 | Modified antibodies containing lgG2 Domains which possess agonist or antagonistic properties and therapeutic use thereof |
| PCT/IB2015/052166 WO2015145360A1 (en) | 2014-03-24 | 2015-03-24 | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019204004A Division JP2020037577A (ja) | 2014-03-24 | 2019-11-11 | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511379A JP2017511379A (ja) | 2017-04-20 |
| JP2017511379A5 true JP2017511379A5 (https=) | 2018-05-17 |
| JP6682498B2 JP6682498B2 (ja) | 2020-04-15 |
Family
ID=52829255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501529A Expired - Fee Related JP6682498B2 (ja) | 2014-03-24 | 2015-03-24 | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
| JP2019204004A Pending JP2020037577A (ja) | 2014-03-24 | 2019-11-11 | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019204004A Pending JP2020037577A (ja) | 2014-03-24 | 2019-11-11 | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11059898B2 (https=) |
| EP (2) | EP3590967A1 (https=) |
| JP (2) | JP6682498B2 (https=) |
| CN (2) | CN113912723A (https=) |
| AU (1) | AU2015237864B2 (https=) |
| CA (1) | CA2943167A1 (https=) |
| WO (1) | WO2015145360A1 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6285923B2 (ja) | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| SI3148579T1 (sl) | 2014-05-28 | 2021-07-30 | Agenus Inc. | Proti GITR antitelesa in postopki z njihovo uporabo |
| PE20170441A1 (es) | 2014-06-06 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| JP6668345B2 (ja) * | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| CN115043943A (zh) | 2015-05-15 | 2022-09-13 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| MX2017015260A (es) | 2015-06-03 | 2018-02-19 | Squibb Bristol Myers Co | Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer. |
| BR112017027549A2 (pt) | 2015-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | anticorpo para cd40 |
| US20190135929A1 (en) | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| CA3004830A1 (en) | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| EP3383908A1 (en) | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| KR20230119259A (ko) * | 2016-04-15 | 2023-08-16 | 이뮤넥스트, 인크. | 항-인간 vista 항체 및 이의 용도 |
| US11859002B2 (en) | 2016-05-13 | 2024-01-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
| EP3493844A4 (en) | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| JP2019533458A (ja) | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| US11535668B2 (en) * | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
| LT3684813T (lt) * | 2017-09-19 | 2026-01-26 | Mab Discovery Gmbh | Agonistiniai cd40 antikūnai |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN111788227B (zh) | 2017-12-27 | 2025-02-25 | 百时美施贵宝公司 | 抗cd40抗体及其用途 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN112740043A (zh) | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | Vista受体 |
| CN112955179A (zh) * | 2018-08-20 | 2021-06-11 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族多肽 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| WO2020069382A1 (en) * | 2018-09-28 | 2020-04-02 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof |
| CN113302205B (zh) * | 2018-11-15 | 2024-12-06 | 综合医院公司 | 激动性肿瘤坏死因子受体超家族多肽 |
| GB201820547D0 (en) * | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN112592404B (zh) * | 2019-09-20 | 2023-07-25 | 上海交通大学医学院 | 抗体活性改造及其筛选方法 |
| CN110669137B (zh) | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN115485302A (zh) | 2020-03-09 | 2022-12-16 | 百时美施贵宝公司 | 具有增强的激动剂活性的针对cd40的抗体 |
| US20240101693A1 (en) * | 2021-01-21 | 2024-03-28 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| CN120693395A (zh) * | 2022-10-20 | 2025-09-23 | 北京三诺佳邑生物技术有限责任公司 | 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体 |
| WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
| EP4560319A1 (en) | 2023-11-24 | 2025-05-28 | Pierre Fabre Medicament | Immune and tumour cells expression of vista in a panel of cancer indications |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2026075989A1 (en) * | 2024-10-01 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Engineered igg molecules and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| AU6445894A (en) | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| JP2007501021A (ja) * | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| CN1922316B (zh) * | 2003-12-25 | 2011-03-23 | 协和发酵麒麟株式会社 | 抗cd40抗体突变体 |
| EP1699826B1 (en) * | 2005-01-05 | 2009-03-11 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| US8716451B2 (en) * | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| US20090304687A1 (en) | 2005-12-09 | 2009-12-10 | Seattle Genetics , Inc. | Methods of using cd40 binding agents |
| EP2158318A2 (en) * | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| AR074438A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal |
| ES2829423T3 (es) * | 2009-04-20 | 2021-05-31 | Kyowa Kirin Co Ltd | Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo |
| JP5469390B2 (ja) * | 2009-07-15 | 2014-04-16 | 日立コンシューマエレクトロニクス株式会社 | 再生信号評価方法及び記録調整方法 |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| KR102049991B1 (ko) * | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
-
2015
- 2015-03-24 AU AU2015237864A patent/AU2015237864B2/en not_active Ceased
- 2015-03-24 EP EP19175308.6A patent/EP3590967A1/en not_active Withdrawn
- 2015-03-24 CN CN202111024797.5A patent/CN113912723A/zh active Pending
- 2015-03-24 EP EP15716147.2A patent/EP3122779B1/en active Active
- 2015-03-24 CN CN201580023010.XA patent/CN107172880B/zh not_active Expired - Fee Related
- 2015-03-24 WO PCT/IB2015/052166 patent/WO2015145360A1/en not_active Ceased
- 2015-03-24 JP JP2017501529A patent/JP6682498B2/ja not_active Expired - Fee Related
- 2015-03-24 US US15/128,781 patent/US11059898B2/en not_active Expired - Fee Related
- 2015-03-24 CA CA2943167A patent/CA2943167A1/en active Pending
-
2019
- 2019-11-11 JP JP2019204004A patent/JP2020037577A/ja active Pending
-
2021
- 2021-05-24 US US17/327,837 patent/US20210347907A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017511379A5 (https=) | ||
| JP2020500010A5 (https=) | ||
| KR102745835B1 (ko) | Tigit- 및 light-기반 키메라 단백질 | |
| JP2022064949A (ja) | 条件付活性ヘテロ二量体ポリペプチド及びその使用方法 | |
| Shimizu et al. | Stimulation of CD25+ CD4+ regulatory T cells through GITR breaks immunological self-tolerance | |
| JP6666267B2 (ja) | Ｏｘ４０ｌ融合タンパク質およびその使用 | |
| JP5883384B2 (ja) | 免疫機能を調節する方法 | |
| CN109071663B (zh) | 双特异性信号传导剂及其用途 | |
| JP2023078394A (ja) | Ｃａｒ－ｔ細胞の調節方法 | |
| US20260097127A1 (en) | Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof | |
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| IL284744B1 (en) | Chimeric antigen receptors gprc5d and cells expressing them | |
| JP2017533207A5 (https=) | ||
| JP2018524326A5 (https=) | ||
| CN119285770A (zh) | Pd-1和pd-l1结合剂 | |
| Vigolo et al. | A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors | |
| JP2017511379A (ja) | アゴニストまたはアンタゴニスト性を誘発する修飾されたＩｇＧ２ドメインを含む修飾された抗体及びその使用 | |
| Wang et al. | Structures of mouse and human GITR–GITRL complexes reveal unique TNF superfamily interactions | |
| EP4516308A2 (en) | Chimeric polypeptides and methods of altering their localization in the cell membrane | |
| US11939367B2 (en) | BTLA fusion protein agonists and uses thereof | |
| Brennan et al. | In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies | |
| CN110381974A (zh) | 基于csf1r的嵌合蛋白 | |
| Shuptrine et al. | Shining a LIGHT on myeloid cell targeted immunotherapy | |
| Ritu et al. | Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics | |
| Nguyen et al. | Quantitative contributions of TNF receptor superfamily members to CD8+ T‐cell responses |